Your browser doesn't support javascript.
loading
Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults.
Gómez-Almaguer, David; Herrera-Rojas, Miguel A; Jaime-Pérez, José C; Gómez-De León, Andrés; Cantú-Rodríguez, Olga G; Gutiérrez-Aguirre, César H; Tarín-Arzaga, Luz; Hernández-Reyes, Jesús; Ruiz-Arguelles, Guillermo J.
Afiliação
  • Gómez-Almaguer D; Hematology Service, Hospital Universitario "Dr José Eleuterio González," Universidad Autónoma de Nuevo León, Monterrey, México;
  • Herrera-Rojas MA; Hematology Service, Hospital Universitario "Dr José Eleuterio González," Universidad Autónoma de Nuevo León, Monterrey, México;
  • Jaime-Pérez JC; Hematology Service, Hospital Universitario "Dr José Eleuterio González," Universidad Autónoma de Nuevo León, Monterrey, México;
  • Gómez-De León A; Hematology Service, Hospital Universitario "Dr José Eleuterio González," Universidad Autónoma de Nuevo León, Monterrey, México;
  • Cantú-Rodríguez OG; Hematology Service, Hospital Universitario "Dr José Eleuterio González," Universidad Autónoma de Nuevo León, Monterrey, México;
  • Gutiérrez-Aguirre CH; Hematology Service, Hospital Universitario "Dr José Eleuterio González," Universidad Autónoma de Nuevo León, Monterrey, México;
  • Tarín-Arzaga L; Hematology Service, Hospital Universitario "Dr José Eleuterio González," Universidad Autónoma de Nuevo León, Monterrey, México;
  • Hernández-Reyes J; Universidad del Valle de México, Villahermosa, México; and Centro de Hematología y Medicina Interna de Puebla, Clínica Ruiz, Universidad de las Américas Puebla, Universidad Popular Autónoma del Estado de Puebla, Puebla, México.
  • Ruiz-Arguelles GJ; Centro de Hematología y Medicina Interna de Puebla, Clínica Ruiz, Universidad de las Américas Puebla, Universidad Popular Autónoma del Estado de Puebla, Puebla, México.
Blood ; 123(25): 3906-8, 2014 Jun 19.
Article em En | MEDLINE | ID: mdl-24802773
Immune thrombocytopenia (ITP) results from platelet destruction and production suppression. Eltrombopag belongs to a new class of thrombopoietin-mimetic drugs that raise platelet counts in ITP patients. We performed a single-arm study to assess the response to a single course of dexamethasone (40 mg by mouth, days 1-4) in combination with eltrombopag (50 mg, days 5-32) in 12 adults with newly diagnosed ITP in an outpatient setting. Median follow-up was 12.5 months. After therapy (day 33), 100% of patients achieved at least ≥30 × 10(9)/L platelets. Four patients relapsed. Complete response at 6 months (platelets ≥100 × 10(9)/L) was achieved in 50% of patients and response at 6 months (platelets ≥30 <100 × 10(9)/L) was achieved in another 25%; relapse-free survival was 66.7% at 12 months (median response duration of 8.3 months). In conclusion, eltrombopag/dexamethasone is a feasible frontline therapy for ITP. This trial is registered at www.clinicaltrials.gov as NCT01652599.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Benzoatos / Dexametasona / Púrpura Trombocitopênica Idiopática / Hidrazinas Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Benzoatos / Dexametasona / Púrpura Trombocitopênica Idiopática / Hidrazinas Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article